Spyre Therapeutics enters the back half of June with a striking tension: the stock has rallied 16% in a week and 31% in a month, yet nearly a fifth of its free float remains borrowed against it.
The options market has flipped decisively bullish, and that shift is the sharpest signal in the data this week. The put/call ratio dropped to 0.31 — almost three standard deviations below its 20-day average of 0.81 — marking one of the most aggressively call-heavy readings of the past year. That's a near-complete reversal of where the market stood just two weeks ago, when the PCR was running above 0.93, consistent with hedging into uncertainty. Something changed; options traders are now leaning hard into upside rather than protecting against downside.
Short interest tells a different story, and the contrast matters. Bears hold 16.5% of the free float short — a high absolute level — but positions have barely moved, edging up just 0.25% over the week after a marginal daily dip on June 23. Borrow costs are low at 0.47%, down from a brief spike above 0.71% in late May. Availability runs at 372% of short interest, meaning roughly three-and-a-half shares are available to borrow for every one already shorted — a loose lending market with no sign of squeeze mechanics building. The short score of 69.3 has been remarkably stable, oscillating in a narrow band all month. Shorts, in aggregate, are not panicking despite a 31% price move working against them.
The Street has been consistently chasing the stock higher, and that momentum is accelerating. Deutsche Bank's David Hoang raised his target to $135 just yesterday — the second time he has lifted it this month, up from $102 on June 4 and then $115 on June 4, now $135. BTIG moved to $112 last week. The consensus mean target stands at $100, which the stock at $97 has nearly reached, but the direction of individual moves is clearly upward and well ahead of the consensus. The bull case centres on SYRE's $225 million cash position, which funds continued IBD pipeline work without near-term dilution pressure. Bears counter that co-formulation complexity and competitor data readouts represent genuine binary risks, and that raising additional capital to advance the pipeline is probable. The price-to-book multiple has expanded roughly 25% over the past 30 days, reflecting the re-rating the market is delivering.
The institutional register shows one unmissable move. Fairmount Funds Management — the fourth-largest holder in the most recent 13-F data — filed a sale of 4.68 million shares at $85.31 on June 23, worth roughly $400 million. That is a material disposal. Fairmount was listed as holding approximately 4 million shares as recently as April, so the discrepancy in share count versus prior holdings warrants attention and may reflect a larger prior position than the last public filing captured. CEO Cameron Turtle and CFO Scott Burrows both sold shares on June 1 at prices in the $69-72 range — before the stock's sharpest leg higher. A director sold $2 million worth at $100 on June 22. The net 90-day insider position is a large positive due to the Fairmount transaction's technical classification, but the directional read from management-level activity is one of consistent selling into strength.
Among correlated peers, the sector is broadly lifting: APGE gained 54% on the week, DSGN rose 23%, and ORKA added 21%. IMVT gained 12.5% and TSHA 15%. SYRE's 16% week fits squarely within a sector-wide re-rating rather than a company-specific catalyst — context worth holding as the next earnings print is scheduled for August 6.
The next meaningful test is whether the stock can hold above the consensus price target going into August, with the Fairmount overhang now disclosed and bears yet to meaningfully cover despite a month of adverse moves.
See the live data behind this article on ORTEX.
Open SYRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
